Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04069247
Other study ID # 2019.044
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 5, 2019
Est. completion date May 30, 2024

Study information

Verified date August 2023
Source Chinese University of Hong Kong
Contact Yun Kwok Wing, MBChB
Phone +852 39197593
Email ykwing@cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to conduct a randomized control trial to validate the treatment effect of e-based cognitive behavioral therapy for Insomnia (eCBT-I) on insomnia disorder, and explore whether eCBT-I could prevent depression and suicide in youths with insomnia and subclinical depression. In addition, to further explore the mechanisms underlying the association between insomnia treatments and psychiatric disorders, this study will evaluate whether changes in candidate factors including insomnia symptoms, poor sleep hygiene, sleep-related unhelpful thoughts and maladaptive behaviors, circadian rhythm disruption and chronic sleep deprivation will mediate the effect of eCBT-I on prevention of depression and suicide.


Description:

Previous studies have documented the associations of insomnia with depression and suicide. Currently, researchers have done considerable work to investigate whether eCBT-I could be effective in improving psychological well-being for adults, and previous studies have confirmed that eCBT-I is effective in reducing depressive symptoms and suicidal ideation in adult population. However, such studies have not been established in youths yet. Additionally, it is still unclear that by which mechanisms eCBT-I might affect mental health, and whether eCBT-I could reduce the risk of depression and suicide. This study will be the first specifically designed investigation of the preventive effects of eCBT-I for depression and suicide in youths, and the first large scale causal test of the relationship between insomnia treatments and psychiatric disorders. The results can be expected to influence care provision for the youth population who are at a life stage of emerging adulthood and vulnerable to psychiatric disorders. Further, because the investigators will be using an eCBT-I approach, a scalable solution may be demonstrated as both feasible and effective. The findings of this study will show the possibility of developing novel preventive intervention for depression and suicide by targeting insomnia.


Recruitment information / eligibility

Status Recruiting
Enrollment 1750
Est. completion date May 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years to 25 Years
Eligibility Inclusion Criteria: 1. Native Han youths in Hong Kong and mainland China, aged between15-25 2. A diagnosis of insomnia disorder measured by ICD-10 Classification of Mental and Behavioural Disorders 3. The presence of moderate or severe insomnia measured by a score of 15 or above on ISI 4. The presence of subclinical depression assessed by a score of between 4 and 20 on PHQ-9 5. Access to smartphones 6. Ability to read and understand research protocol Exclusion Criteria: 1. Shift workers 2. The presence of suicide plans and suicide attempts measured by MINI via telephone interview 3. A reported diagnosis of psychosis, schizophrenia, bipolar disorders, or neurodevelopmental disorders 4. Medical conditions that could cause poor sleep quality and sleep continuity disruption, such as eczema, gastro-oesophageal and reflux disease 5. An additional sleep disorder (other than insomnia) that may potentially contribute to a disruption in sleep continuity and quality, such as excessive sleepiness and possible obstructive sleep apnoea 6. The presence of current major depressive disorder measured by MINI via telephone interview 7. Women during pregnancy or lactation 8. Currently receiving psychological treatment for insomnia provided by a psychologist

Study Design


Related Conditions & MeSH terms

  • Insomnia
  • Sleep Initiation and Maintenance Disorders

Intervention

Behavioral:
ECBT-I
The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
HE
The HE will be delivered in control though a mobile application (eSleep) with a personal password.

Locations

Country Name City State
China Peking University Sixth Hospital Beijing
Hong Kong Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
Chinese University of Hong Kong Peking University Sixth Hospital

Countries where clinical trial is conducted

China,  Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Other Change of suicidal ideation Suicidal ideation will be measured by Beck Scale for Suicide Ideation (BSSI). BSSI is a 19-item self-report measure designed to assess suicidality, with higher total scores representing greater. Scores range from 0 to 38. Baseline, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of daytime symptoms Daytime symptoms will be measured by Multidimensional Fatigue Inventory (MFI). MFI is a 20-item self-rated scale on fatigue symptoms. There are three subscales, measuring the physical (possibly scored from 7 to 35), mental (possibly scored from 6 to 30), and spiritual (possibly scored from 7 to 35), dimensions of fatigue. A grand total score can be calculated by summing up the three sub scores. In all cases, a higher score represents higher fatigue symptoms. Baseline, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of sleep-related thoughts and behaviors Sleep-related thoughts and behaviors will be measured by Brief Version of Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16). DBAS-16 is a 16-item self-report measure designed to evaluate a subset of those sleep related cognition, with a higher score indicating more dysfunctional beliefs and attitudes about sleep. The total score is calculated from the average score of all the items on the scale and could range from 0 to 10. Baseline, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of circadian rhythms Circadian rhythms will be measured by reduced version of Horne and Östberg Morningness-Eveningness Questionnaire (rMEQ). The rMEQ is a 5-item self reported measure used to evaluate circadian rhythm and sleep rhythm patterns in individuals. Individuals scored higher than 17 and lower than 12 were classified as morning-type and evening-type, respectively. Individuals scored between 12 and 17 were classified as intermediate-type. Scores range from 4 to 25. Baseline, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of subjective sleep measure (time in bed, TIB) TIB will be estimated by 7-Day Daily Sleep Diary. 7-Day Daily Sleep Diary is a prospective measure that includes the questions to assess bedtime, time to fall asleep, total length of time awake during the night, number of awakenings during the night, final wake time and rise time, time spent in bed, total sleep time, sleep quality during the previous night (rating 0-10). Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of subjective sleep measure (total sleep time, TST) TST will be estimated by 7-Day Daily Sleep Diary. 7-Day Daily Sleep Diary is a prospective measure that includes the questions to assess bedtime, time to fall asleep, total length of time awake during the night, number of awakenings during the night, final wake time and rise time, time spent in bed, total sleep time, sleep quality during the previous night (rating 0-10). Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of subjective sleep measure (sleep onset latency, SOL) SOL will be estimated by 7-Day Daily Sleep Diary. 7-Day Daily Sleep Diary is a prospective measure that includes the questions to assess bedtime, time to fall asleep, total length of time awake during the night, number of awakenings during the night, final wake time and rise time, time spent in bed, total sleep time, sleep quality during the previous night (rating 0-10). Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of subjective sleep measure (wake after sleep onset, WASO) WASO will be estimated by 7-Day Daily Sleep Diary. 7-Day Daily Sleep Diary is a prospective measure that includes the questions to assess bedtime, time to fall asleep, total length of time awake during the night, number of awakenings during the night, final wake time and rise time, time spent in bed, total sleep time, sleep quality during the previous night (rating 0-10). Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Other Change of subjective sleep measure (sleep efficiency, SE) SE will be estimated by 7-Day Daily Sleep Diary. 7-Day Daily Sleep Diary is a prospective measure that includes the questions to assess bedtime, time to fall asleep, total length of time awake during the night, number of awakenings during the night, final wake time and rise time, time spent in bed, total sleep time, sleep quality during the previous night (rating 0-10). Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Primary Remission rate of insomnia disorder Insomnia disorder will be confirmed by International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Post-treatment (week 7/at the conclusion of last session)
Primary Remission rate of insomnia disorder Insomnia disorder will be confirmed by International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. 6-month follow-up
Primary Remission rate of insomnia disorder Insomnia disorder will be confirmed by International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. 12-month follow-up
Primary Change of insomnia symptoms Insomnia symptoms will be measured by Insomnia Severity Index (ISI). ISI is a seven-item self-report measure designed to assess the nature, severity and impact of insomnia, with a higher total score suggesting more severe insomnia symptoms. Scores range from 0 to 28. Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Primary New incidence of major depressive disorder Major depressive disorder will be confirmed by Mini International Neuropsychiatric Interview (MINI). Post-treatment (week 7/at the conclusion of last session)
Primary New incidence of major depressive disorder Major depressive disorder will be confirmed by Mini International Neuropsychiatric Interview (MINI). 6-month follow-up
Primary New incidence of major depressive disorder Major depressive disorder will be confirmed by Mini International Neuropsychiatric Interview (MINI). 12-month follow-up
Primary Change of depressive symptoms Depressive symptoms will be measured by Patient Health Questionnaire-9 (PHQ-9). PHQ-9 is a commonly used self-administered questionnaire to assess depressive symptoms and severity, with a higher total score suggesting more severe depressive symptoms. Scores range from 0 to 27. Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
Secondary New incidence of suicidality Suicidality which includes suicidal ideation, suicide plans and suicide attempts will be measured by MINI. Post-treatment (week 7/at the conclusion of last session)
Secondary New incidence of suicidality Suicidality which includes suicidal ideation, suicide plans and suicide attempts will be measured by MINI. 6-month follow-up
Secondary New incidence of suicidality Suicidality which includes suicidal ideation, suicide plans and suicide attempts will be measured by MINI. 12-month follow-up
Secondary Change of anxiety symptoms Anxiety symptoms will be measured by Generalised Anxiety Disorder 7-item (GAD-7). GAD-7 is a self-report measure of anxiety severity, with a higher total score suggesting more severe anxiety symptoms. Scores range from 0 to 21. Baseline, week 3/at the conclusion of session 2, week 5/at the conclusion of session 4, post-treatment (week 7/at the conclusion of last session), 6-month follow-up and 12-month follow-up
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A
Not yet recruiting NCT03194191 - Pregnancy With Insomnia: a Trial of Acupuncture N/A